Lilly halts trial of experimental Alzheimers drug
The trial ended after participants showed abnormal liver biochemistry, the Indianapolis-based drugmaker said Thursday in a statement.
The trial ended after participants showed abnormal liver biochemistry, the Indianapolis-based drugmaker said Thursday in a statement.
Starting July 1, pharmacists will be able to offer a much wider variety of immunizations to customers, in an effort from lawmakers to make health care more accessible.
The study results, which will be released Monday afternoon, are part of Indianapolis-based Lilly’s campaign to get Medicare to pay for use of its brain imaging agent Amyvid.
Eli Lilly claims recent decisions by Canadian courts invalidating 17 drug patents have made the country an outlier among major developed countries.
The drug, enzastaurin, was in the most advanced stage of testing and had been expected to generate $260 million in annual sales by 2018.
Lilly will eliminate 1,624 positions from its U.S. sales force in July, according to a notice the company made to state officials. But some of those workers may be rehired by the firm.
Major drugmakers, including Indianapolis-based Eli Lilly and Co., are closely watching Pfizer Inc.’s plan to sell Viagra directly to consumers. The bold move blows up the drug industry’s distribution model.
Eli Lilly and Co. is seeking to revoke a patent held by a Johnson & Johnson unit, arguing at a London court it might delay availability of a potential treatment for Alzheimer’s disease.
A pharmacy that makes specialty medications is recalling nearly 100 compounded drugs after federal regulators found potential safety problems during an inspection.
Investors are gaining confidence in the ability of major drugmakers, including Eli Lilly and Co., to improve their pipelines of new products. The big pharma firms begin to report first-quarter earnings this week.
The pharmaceutical firm has $400 million in projects in the works for its facilities south of downtown. City officials have advanced its request for tax breaks to a public hearing and final consideration May 1.
Indianapolis development officials on Wednesday will weigh the 10-year requests from the pharmaceuticals giant related to a new manufacturing plant and improvements to existing operations downtown.
The Indianapolis pharmaceuticals giant said Thursday that it would lay off hundreds of U.S. sales reps, as it prepares for the loss of patent protection on two of its best-selling drugs.
Johnson & Johnson, the world’s largest seller of health-care products, won approval for the first in a new family of diabetes drugs, giving them the edge against rivals including Eli Lilly and Co. that are developing similar medicines.
Eli Lilly and Co. said Monday that it has submitted a new type 2 diabetes treatment it is developing with German drugmaker Boehringer Ingelheim to the Food and Drug Administration.
Consumers would face tighter limits on the quantities they could buy of cold and allergy pills often used to make methamphetamine under a proposal approved by Indiana lawmakers.
Federal regulators are pressing the Supreme Court to stop big pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs. They argue these deals deny American consumers, usually for years, steep price declines.
More than two dozen of the world's largest pharmaceutical companies, including Indianapolis-based Eli Lilly and Co., have agreed to provide funding and other support to Interpol's battle against counterfeit prescription drugs.
Eli Lilly and Co. has sued Roche Holding AG’s Genentech unit, asking a court to invalidate patents used to make treatments for cancer and autoimmune diseases.
Endocyte Inc. saw its shares fall nearly 7 percent Tuesday morning after the drug development firm announced that its application for U.S. approval of a cancer drug could be delayed another 10 months.